CKLF and neoplasm: For drug resistant HCC, Kanglaite Injection pretreatment may sensitize HepG2 cells to cisplatin partly by inhibiting the transporter-mediated drug efflux as well as the chemokine like factor (CKLF1)-mediated NF-κB pathway that may contribute to inflammation of tumor microenvironment and chemoresistance [258].